English
简体中文
Total: £ 56.28
Published Date: 2025-10-15 | Pages: 131 | Tables: 143 | Medical Care
The global Chronic Kidney Disease Medication market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Chronic Kidney Disease (CKD) Medication refers to a class of drugs specifically designed to manage and treat the progression of chronic kidney disease, a long-term condition characterized by the gradual loss of kidney function. These medications address various aspects of CKD, such as controlling blood pressure, managing blood sugar levels, correcting electrolyte imbalances, and treating complications like anemia and bone disease. The primary goal of CKD medications is to slow down kidney damage, alleviate symptoms, and improve the patient's quality of life.
From a downstream perspective, Hospital accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Chronic Kidney Disease Medication leading manufacturers including Amgen, Roche, FibroGen, AstraZeneca, GlaxoSmithKline, Akebia Therapeutics, Kissei, Teva Pharmaceutical Industries, Pfizer, Sanofi, etc., dominate supply; the top five capture approximately % of global revenue, with Amgen leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Chronic Kidney Disease Medication market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Amgen
Roche
FibroGen
AstraZeneca
GlaxoSmithKline
Akebia Therapeutics
Kissei
Teva Pharmaceutical Industries
Pfizer
Sanofi
Novartis
Segment by Type
Angiotensin-Converting Enzyme (ACE) Inhibitors
Angiotensin II Receptor Blockers (ARBs)
Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors
Others
Segment by Application
Hospital
Specialist Clinic
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Chronic Kidney Disease Medication study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Study Coverage
1.1 Introduction to Chronic Kidney Disease Medication: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Chronic Kidney Disease Medication Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Angiotensin-Converting Enzyme (ACE) Inhibitors
1.2.3 Angiotensin II Receptor Blockers (ARBs)
1.2.4 Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors
1.2.5 Others
1.3 Market Segmentation by Application
1.3.1 Global Chronic Kidney Disease Medication Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Specialist Clinic
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Chronic Kidney Disease Medication Revenue Estimates and Forecasts 2020-2031
2.2 Global Chronic Kidney Disease Medication Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Chronic Kidney Disease Medication Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Chronic Kidney Disease Medication Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Angiotensin-Converting Enzyme (ACE) Inhibitors Market Size by Players
3.3.2 Angiotensin II Receptor Blockers (ARBs) Market Size by Players
3.3.3 Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors Market Size by Players
3.3.4 Others Market Size by Players
3.4 Global Chronic Kidney Disease Medication Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Chronic Kidney Disease Medication Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Chronic Kidney Disease Medication Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Chronic Kidney Disease Medication Market Size by Type (2020-2031)
6.4 North America Chronic Kidney Disease Medication Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Chronic Kidney Disease Medication Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Chronic Kidney Disease Medication Market Size by Type (2020-2031)
7.4 Europe Chronic Kidney Disease Medication Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Chronic Kidney Disease Medication Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Chronic Kidney Disease Medication Market Size by Type (2020-2031)
8.4 Asia-Pacific Chronic Kidney Disease Medication Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Chronic Kidney Disease Medication Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Chronic Kidney Disease Medication Market Size by Type (2020-2031)
9.4 Central and South America Chronic Kidney Disease Medication Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Chronic Kidney Disease Medication Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Chronic Kidney Disease Medication Market Size by Type (2020-2031)
10.4 Middle East and Africa Chronic Kidney Disease Medication Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Chronic Kidney Disease Medication Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Amgen
11.1.1 Amgen Corporation Information
11.1.2 Amgen Business Overview
11.1.3 Amgen Chronic Kidney Disease Medication Product Features and Attributes
11.1.4 Amgen Chronic Kidney Disease Medication Revenue and Gross Margin (2020-2025)
11.1.5 Amgen Chronic Kidney Disease Medication Revenue by Product in 2024
11.1.6 Amgen Chronic Kidney Disease Medication Revenue by Application in 2024
11.1.7 Amgen Chronic Kidney Disease Medication Revenue by Geographic Area in 2024
11.1.8 Amgen Chronic Kidney Disease Medication SWOT Analysis
11.1.9 Amgen Recent Developments
11.2 Roche
11.2.1 Roche Corporation Information
11.2.2 Roche Business Overview
11.2.3 Roche Chronic Kidney Disease Medication Product Features and Attributes
11.2.4 Roche Chronic Kidney Disease Medication Revenue and Gross Margin (2020-2025)
11.2.5 Roche Chronic Kidney Disease Medication Revenue by Product in 2024
11.2.6 Roche Chronic Kidney Disease Medication Revenue by Application in 2024
11.2.7 Roche Chronic Kidney Disease Medication Revenue by Geographic Area in 2024
11.2.8 Roche Chronic Kidney Disease Medication SWOT Analysis
11.2.9 Roche Recent Developments
11.3 FibroGen
11.3.1 FibroGen Corporation Information
11.3.2 FibroGen Business Overview
11.3.3 FibroGen Chronic Kidney Disease Medication Product Features and Attributes
11.3.4 FibroGen Chronic Kidney Disease Medication Revenue and Gross Margin (2020-2025)
11.3.5 FibroGen Chronic Kidney Disease Medication Revenue by Product in 2024
11.3.6 FibroGen Chronic Kidney Disease Medication Revenue by Application in 2024
11.3.7 FibroGen Chronic Kidney Disease Medication Revenue by Geographic Area in 2024
11.3.8 FibroGen Chronic Kidney Disease Medication SWOT Analysis
11.3.9 FibroGen Recent Developments
11.4 AstraZeneca
11.4.1 AstraZeneca Corporation Information
11.4.2 AstraZeneca Business Overview
11.4.3 AstraZeneca Chronic Kidney Disease Medication Product Features and Attributes
11.4.4 AstraZeneca Chronic Kidney Disease Medication Revenue and Gross Margin (2020-2025)
11.4.5 AstraZeneca Chronic Kidney Disease Medication Revenue by Product in 2024
11.4.6 AstraZeneca Chronic Kidney Disease Medication Revenue by Application in 2024
11.4.7 AstraZeneca Chronic Kidney Disease Medication Revenue by Geographic Area in 2024
11.4.8 AstraZeneca Chronic Kidney Disease Medication SWOT Analysis
11.4.9 AstraZeneca Recent Developments
11.5 GlaxoSmithKline
11.5.1 GlaxoSmithKline Corporation Information
11.5.2 GlaxoSmithKline Business Overview
11.5.3 GlaxoSmithKline Chronic Kidney Disease Medication Product Features and Attributes
11.5.4 GlaxoSmithKline Chronic Kidney Disease Medication Revenue and Gross Margin (2020-2025)
11.5.5 GlaxoSmithKline Chronic Kidney Disease Medication Revenue by Product in 2024
11.5.6 GlaxoSmithKline Chronic Kidney Disease Medication Revenue by Application in 2024
11.5.7 GlaxoSmithKline Chronic Kidney Disease Medication Revenue by Geographic Area in 2024
11.5.8 GlaxoSmithKline Chronic Kidney Disease Medication SWOT Analysis
11.5.9 GlaxoSmithKline Recent Developments
11.6 Akebia Therapeutics
11.6.1 Akebia Therapeutics Corporation Information
11.6.2 Akebia Therapeutics Business Overview
11.6.3 Akebia Therapeutics Chronic Kidney Disease Medication Product Features and Attributes
11.6.4 Akebia Therapeutics Chronic Kidney Disease Medication Revenue and Gross Margin (2020-2025)
11.6.5 Akebia Therapeutics Recent Developments
11.7 Kissei
11.7.1 Kissei Corporation Information
11.7.2 Kissei Business Overview
11.7.3 Kissei Chronic Kidney Disease Medication Product Features and Attributes
11.7.4 Kissei Chronic Kidney Disease Medication Revenue and Gross Margin (2020-2025)
11.7.5 Kissei Recent Developments
11.8 Teva Pharmaceutical Industries
11.8.1 Teva Pharmaceutical Industries Corporation Information
11.8.2 Teva Pharmaceutical Industries Business Overview
11.8.3 Teva Pharmaceutical Industries Chronic Kidney Disease Medication Product Features and Attributes
11.8.4 Teva Pharmaceutical Industries Chronic Kidney Disease Medication Revenue and Gross Margin (2020-2025)
11.8.5 Teva Pharmaceutical Industries Recent Developments
11.9 Pfizer
11.9.1 Pfizer Corporation Information
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Chronic Kidney Disease Medication Product Features and Attributes
11.9.4 Pfizer Chronic Kidney Disease Medication Revenue and Gross Margin (2020-2025)
11.9.5 Pfizer Recent Developments
11.10 Sanofi
11.10.1 Sanofi Corporation Information
11.10.2 Sanofi Business Overview
11.10.3 Sanofi Chronic Kidney Disease Medication Product Features and Attributes
11.10.4 Sanofi Chronic Kidney Disease Medication Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Novartis
11.11.1 Novartis Corporation Information
11.11.2 Novartis Business Overview
11.11.3 Novartis Chronic Kidney Disease Medication Product Features and Attributes
11.11.4 Novartis Chronic Kidney Disease Medication Revenue and Gross Margin (2020-2025)
11.11.5 Novartis Recent Developments
12 Chronic Kidney Disease MedicationIndustry Chain Analysis
12.1 Chronic Kidney Disease Medication Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Chronic Kidney Disease Medication Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Chronic Kidney Disease Medication Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Chronic Kidney Disease Medication Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Chronic Kidney Disease Medication Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Chronic Kidney Disease Medication Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Chronic Kidney Disease Medication Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Chronic Kidney Disease Medication Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Chronic Kidney Disease Medication Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Chronic Kidney Disease Medication Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Chronic Kidney Disease Medication by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Kidney Disease Medication as of 2024)
Table 11. Global Chronic Kidney Disease Medication Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Chronic Kidney Disease Medication Companies Headquarters
Table 13. Global Chronic Kidney Disease Medication Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Chronic Kidney Disease Medication Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Chronic Kidney Disease Medication Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Chronic Kidney Disease Medication Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Chronic Kidney Disease Medication Revenue by Application (2026-2031) & (US$ Million)
Table 21. Chronic Kidney Disease Medication High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Chronic Kidney Disease Medication Growth Accelerators and Market Barriers
Table 25. North America Chronic Kidney Disease Medication Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Chronic Kidney Disease Medication Growth Accelerators and Market Barriers
Table 27. Europe Chronic Kidney Disease Medication Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Chronic Kidney Disease Medication Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Chronic Kidney Disease Medication Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Chronic Kidney Disease Medication Investment Opportunities and Key Challenges
Table 31. Central and South America Chronic Kidney Disease Medication Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Chronic Kidney Disease Medication Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Chronic Kidney Disease Medication Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Amgen Corporation Information
Table 35. Amgen Description and Major Businesses
Table 36. Amgen Product Features and Attributes
Table 37. Amgen Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Amgen Revenue Proportion by Product in 2024
Table 39. Amgen Revenue Proportion by Application in 2024
Table 40. Amgen Revenue Proportion by Geographic Area in 2024
Table 41. Amgen Chronic Kidney Disease Medication SWOT Analysis
Table 42. Amgen Recent Developments
Table 43. Roche Corporation Information
Table 44. Roche Description and Major Businesses
Table 45. Roche Product Features and Attributes
Table 46. Roche Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Roche Revenue Proportion by Product in 2024
Table 48. Roche Revenue Proportion by Application in 2024
Table 49. Roche Revenue Proportion by Geographic Area in 2024
Table 50. Roche Chronic Kidney Disease Medication SWOT Analysis
Table 51. Roche Recent Developments
Table 52. FibroGen Corporation Information
Table 53. FibroGen Description and Major Businesses
Table 54. FibroGen Product Features and Attributes
Table 55. FibroGen Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. FibroGen Revenue Proportion by Product in 2024
Table 57. FibroGen Revenue Proportion by Application in 2024
Table 58. FibroGen Revenue Proportion by Geographic Area in 2024
Table 59. FibroGen Chronic Kidney Disease Medication SWOT Analysis
Table 60. FibroGen Recent Developments
Table 61. AstraZeneca Corporation Information
Table 62. AstraZeneca Description and Major Businesses
Table 63. AstraZeneca Product Features and Attributes
Table 64. AstraZeneca Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. AstraZeneca Revenue Proportion by Product in 2024
Table 66. AstraZeneca Revenue Proportion by Application in 2024
Table 67. AstraZeneca Revenue Proportion by Geographic Area in 2024
Table 68. AstraZeneca Chronic Kidney Disease Medication SWOT Analysis
Table 69. AstraZeneca Recent Developments
Table 70. GlaxoSmithKline Corporation Information
Table 71. GlaxoSmithKline Description and Major Businesses
Table 72. GlaxoSmithKline Product Features and Attributes
Table 73. GlaxoSmithKline Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. GlaxoSmithKline Revenue Proportion by Product in 2024
Table 75. GlaxoSmithKline Revenue Proportion by Application in 2024
Table 76. GlaxoSmithKline Revenue Proportion by Geographic Area in 2024
Table 77. GlaxoSmithKline Chronic Kidney Disease Medication SWOT Analysis
Table 78. GlaxoSmithKline Recent Developments
Table 79. Akebia Therapeutics Corporation Information
Table 80. Akebia Therapeutics Description and Major Businesses
Table 81. Akebia Therapeutics Product Features and Attributes
Table 82. Akebia Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Akebia Therapeutics Recent Developments
Table 84. Kissei Corporation Information
Table 85. Kissei Description and Major Businesses
Table 86. Kissei Product Features and Attributes
Table 87. Kissei Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Kissei Recent Developments
Table 89. Teva Pharmaceutical Industries Corporation Information
Table 90. Teva Pharmaceutical Industries Description and Major Businesses
Table 91. Teva Pharmaceutical Industries Product Features and Attributes
Table 92. Teva Pharmaceutical Industries Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Teva Pharmaceutical Industries Recent Developments
Table 94. Pfizer Corporation Information
Table 95. Pfizer Description and Major Businesses
Table 96. Pfizer Product Features and Attributes
Table 97. Pfizer Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Pfizer Recent Developments
Table 99. Sanofi Corporation Information
Table 100. Sanofi Description and Major Businesses
Table 101. Sanofi Product Features and Attributes
Table 102. Sanofi Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Sanofi Recent Developments
Table 104. Novartis Corporation Information
Table 105. Novartis Description and Major Businesses
Table 106. Novartis Product Features and Attributes
Table 107. Novartis Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Novartis Recent Developments
Table 109. Raw Materials Key Suppliers
Table 110. Distributors List
Table 111. Market Trends and Market Evolution
Table 112. Market Drivers and Opportunities
Table 113. Market Challenges, Risks, and Restraints
Table 114. Research Programs/Design for This Report
Table 115. Key Data Information from Secondary Sources
Table 116. Key Data Information from Primary Sources
List of Figures
Figure 1. Chronic Kidney Disease Medication Product Picture
Figure 2. Global Chronic Kidney Disease Medication Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Angiotensin-Converting Enzyme (ACE) Inhibitors Product Picture
Figure 4. Angiotensin II Receptor Blockers (ARBs) Product Picture
Figure 5. Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors Product Picture
Figure 6. Others Product Picture
Figure 7. Global Chronic Kidney Disease Medication Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 8. Hospital
Figure 9. Specialist Clinic
Figure 10. Chronic Kidney Disease Medication Report Years Considered
Figure 11. Global Chronic Kidney Disease Medication Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Chronic Kidney Disease Medication Revenue (2020-2031) & (US$ Million)
Figure 13. Global Chronic Kidney Disease Medication Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 14. Global Chronic Kidney Disease Medication Revenue Market Share by Region (2020-2031)
Figure 15. Global Chronic Kidney Disease Medication Revenue Market Share Ranking (2024)
Figure 16. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 17. Angiotensin-Converting Enzyme (ACE) Inhibitors Revenue Market Share by Player in 2024
Figure 18. Angiotensin II Receptor Blockers (ARBs) Revenue Market Share by Player in 2024
Figure 19. Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors Revenue Market Share by Player in 2024
Figure 20. Others Revenue Market Share by Player in 2024
Figure 21. Global Chronic Kidney Disease Medication Revenue Market Share by Type (2020-2031)
Figure 22. Global Chronic Kidney Disease Medication Revenue Market Share by Application (2020-2031)
Figure 23. North America Chronic Kidney Disease Medication Revenue YoY (2020-2031) & (US$ Million)
Figure 24. North America Top 5 Players Chronic Kidney Disease Medication Revenue (US$ Million) in 2024
Figure 25. North America Chronic Kidney Disease Medication Revenue (US$ Million) by Type (2020 - 2031)
Figure 26. North America Chronic Kidney Disease Medication Revenue (US$ Million) by Application (2020-2031)
Figure 27. US Chronic Kidney Disease Medication Revenue (2020-2031) & (US$ Million)
Figure 28. Canada Chronic Kidney Disease Medication Revenue (2020-2031) & (US$ Million)
Figure 29. Mexico Chronic Kidney Disease Medication Revenue (2020-2031) & (US$ Million)
Figure 30. Europe Chronic Kidney Disease Medication Revenue YoY (2020-2031) & (US$ Million)
Figure 31. Europe Top 5 Players Chronic Kidney Disease Medication Revenue (US$ Million) in 2024
Figure 32. Europe Chronic Kidney Disease Medication Revenue (US$ Million) by Type (2020-2031)
Figure 33. Europe Chronic Kidney Disease Medication Revenue (US$ Million) by Application (2020-2031)
Figure 34. Germany Chronic Kidney Disease Medication Revenue (2020-2031) & (US$ Million)
Figure 35. France Chronic Kidney Disease Medication Revenue (2020-2031) & (US$ Million)
Figure 36. U.K. Chronic Kidney Disease Medication Revenue (2020-2031) & (US$ Million)
Figure 37. Italy Chronic Kidney Disease Medication Revenue (2020-2031) & (US$ Million)
Figure 38. Russia Chronic Kidney Disease Medication Revenue (2020-2031) & (US$ Million)
Figure 39. Asia-Pacific Chronic Kidney Disease Medication Revenue YoY (2020-2031) & (US$ Million)
Figure 40. Asia-Pacific Top 8 Players Chronic Kidney Disease Medication Revenue (US$ Million) in 2024
Figure 41. Asia-Pacific Chronic Kidney Disease Medication Revenue (US$ Million) by Type (2020-2031)
Figure 42. Asia-Pacific Chronic Kidney Disease Medication Revenue (US$ Million) by Application (2020-2031)
Figure 43. Indonesia Chronic Kidney Disease Medication Revenue (2020-2031) & (US$ Million)
Figure 44. Japan Chronic Kidney Disease Medication Revenue (2020-2031) & (US$ Million)
Figure 45. South Korea Chronic Kidney Disease Medication Revenue (2020-2031) & (US$ Million)
Figure 46. Australia Chronic Kidney Disease Medication Revenue (2020-2031) & (US$ Million)
Figure 47. India Chronic Kidney Disease Medication Revenue (2020-2031) & (US$ Million)
Figure 48. Indonesia Chronic Kidney Disease Medication Revenue (2020-2031) & (US$ Million)
Figure 49. Vietnam Chronic Kidney Disease Medication Revenue (2020-2031) & (US$ Million)
Figure 50. Malaysia Chronic Kidney Disease Medication Revenue (2020-2031) & (US$ Million)
Figure 51. Philippines Chronic Kidney Disease Medication Revenue (2020-2031) & (US$ Million)
Figure 52. Singapore Chronic Kidney Disease Medication Revenue (2020-2031) & (US$ Million)
Figure 53. Central and South America Chronic Kidney Disease Medication Revenue YoY (2020-2031) & (US$ Million)
Figure 54. Central and South America Top 5 Players Chronic Kidney Disease Medication Revenue (US$ Million) in 2024
Figure 55. Central and South America Chronic Kidney Disease Medication Revenue (US$ Million) by Type (2020-2031)
Figure 56. Central and South America Chronic Kidney Disease Medication Revenue (US$ Million) by Application (2020-2031)
Figure 57. Brazil Chronic Kidney Disease Medication Revenue (2020-2025) & (US$ Million)
Figure 58. Argentina Chronic Kidney Disease Medication Revenue (2020-2025) & (US$ Million)
Figure 59. Middle East and Africa Chronic Kidney Disease Medication Revenue YoY (2020-2031) & (US$ Million)
Figure 60. Middle East and Africa Top 5 Players Chronic Kidney Disease Medication Revenue (US$ Million) in 2024
Figure 61. South America Chronic Kidney Disease Medication Revenue (US$ Million) by Type (2020-2031)
Figure 62. Middle East and Africa Chronic Kidney Disease Medication Revenue (US$ Million) by Application (2020-2031)
Figure 63. GCC Countries Chronic Kidney Disease Medication Revenue (2020-2025) & (US$ Million)
Figure 64. Israel Chronic Kidney Disease Medication Revenue (2020-2025) & (US$ Million)
Figure 65. Egypt Chronic Kidney Disease Medication Revenue (2020-2025) & (US$ Million)
Figure 66. South Africa Chronic Kidney Disease Medication Revenue (2020-2025) & (US$ Million)
Figure 67. Chronic Kidney Disease Medication Industry Chain Mapping
Figure 68. Channels of Distribution (Direct Vs Distribution)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
